Relationship between Serum ProGRP,TSGF and Outcome and Prognosis of Patients with EGFR Mutation-Positive Advanced Non-small Cell Lung Cancer
Objective:To investigate the relationship between serum progastrin-releasing peptide(ProGRP),tumor-specific growth factor(TSGF)and the efficacy and prognosis of patients with epidermal growth factor receptor(EGFR)mutation-positive advanced non-small cell lung cancer(NSCLC).Methods:A total of 95 EGFR mutation positive advanced NSCLC patients treated with EGFR-tyrosine kinase inhibitors in Qingdao Traditional Chinese Medicine Hospital,Qingdao Hongdao People's Hospital,Qingdao Jiaoyun Geriatric Hospital,Qingdao Chest Hospital from January 2017 to January 2020 were selected.All patients were divided into effective and ineffective groups according to the efficacy and the difference in serum ProGRP and TSGF between the valid and ineffective groups was detected by chemiluminescence and rate methods.EGFR mutation positive patients and median survival time,according to the mean of serum ProGRP(365.73±14.35)pg/mL,TSGF(147.88±27.73 pg/mL,41 patients),high TSGF(147.88 U,46 patients),low ProGRP(＜365.73 pg/mL,54 patients),and low TSGF(＜347.88 U/mL,49 patients).Survival curves of EGFR mutation-positive advanced NSCLC patients with high/low serum ProGRP and TSGF levels were plotted using the Kaplan-Meier method.And the patients with EGFR mutation-positive advanced NSCLC were divided into death group(56 cases)and survival group(39 cases)according to the prognosis.Factors affecting the prognosis of EGFR.mutation-positive advanced NSCLC patients were analyzed using univariate and multivariate Cox regression,and the predictive value of serum ProGRP and TSGF levels in EGFR mutation-positive advanced NSCLC patients was analyzed by using receiver operating characteristic(ROC)curves.Results:After 6 weeks of treatment,the serum ProGRP and TSGF levels were higher in the ineffective group than in the effective group(P＜0.05).There were no cases lost to follow-up during follow-up,the objective response rate of 95 EGFR mutation-positive advanced NSCLC was 70.53％(67/95),a 3-year overall survival rate of 41.05％(39/95),and a median survival time of 16.00 months.The Kaplan-Meier curve analysis showed that the overall survival rate and median survival time in the high ProGRP and high TSGF groups were lower than those in the low ProGRP and low TSGF groups(P＜0.05).Univariate and multivariate Cox regression analysis showed that,TNM stage IV,poor differentiation,elevated ProGRP and elevated TSGF were independent risk factors affecting the prognosis of patients with EGFR mutation-positive advanced NSCLC(P＜0.05).ROC curve analysis showed that,the area under the curve of serum ProGRP and TSGF levels in predicting the death of patients with EGFR mutation-positive advanced NSCLC was 0.879,which was greater than 0.765 and 0.773 predicted by serum ProGRP and TSGF levels alone.Conclusions:Elevated serum ProGRP and TSGF levels are closely related to the efficacy and prognosis of patients with EGFR mutation-positive advanced NSCLC,and the combined detection of serum ProGRP and TSGF levels has a high predictive value for them.
NETL
NSTL
万方数据
